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Available online 23 January 2017Introduction:Many drugs are unavailable in suitable oral paediatric dosage forms, and pharmacists often have to
compound drugs to provide paediatric patients with an acceptable formulation in the right dose. Liquid formu-
lations offer the advantage of dosing ﬂexibility and ease of administration to young patients, but drug substances
often showpoor aqueous solubility. The objective of this workwas to study different solvents andmatrices to de-
sign a liquid formulation for poorly water soluble drugs, using lorazepam as model drug.
Methods: Three different formulation strategieswere explored to improve the solubility. Firstly, water-soluble or-
ganic solvents were used to improve the aqueous solubility directly, secondly, ionic surfactants were used to sol-
ubilise the model drug, and thirdly, complexation of lorazepamwith cyclodextrin was studied. Speciﬁc attention
was paid to excipients, adequate taste correction and palatability. For theﬁnal formulation, physical and chemical
stability and microbiological quality were assessed for 12 months.
Results:An organic solvent based formulation, containing amixture of polyethylene glycol and glycerol 85%,with
aminimum amount of propylene glycol, proved to be physically and chemically stable. Development of the non-
ionic surfactants formulation was discontinued due to taste problems. The cyclodextrin formulationswere phys-
ically stable, but lorazepam content declined to 90% within ﬁve months. The ﬁnal formulation contained in vol-
ume concentration (%v/v) 87% glycerol, 10% polyethylene glycol 400 and 3% propylene glycol. Orange essence
was the preferred taste corrector. The formulation remained stable for 12months at 4 °C,with lorazepam content
remaining N95%. Related substances increased during the study period but remained below 2%. In-use stability
was proven up to 4 weeks.
Conclusion: An organic solvent based oral formulation was shown to be superior to a non-ionic surfactant based
formulation or a cyclodextrin formulation. These results may help to formulate paediatric formulations of other
poorly water soluble drugs, to aid pharmacy compounding.
© 2017 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).Keywords:
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HP-β-CD1. Introduction
Many drugs are unavailable in suitable oral paediatric dosage forms
(van Riet-Nales et al., 2011), therefore, pharmacists often have to com-
pound drugs to provide paediatric patients with an acceptable formula-
tion in the right dose. In the reﬂection paper released by the paediatric
working party of the EuropeanMedicines Agency (EMA) on formulations
of choice for the paediatric population, solutions/drops and effervescent
dosage forms are considered to have the highest applicability in a popu-
lation of young patients (Committee for Human Medicinal Productsan der Vossen).
.V. This is an open access article und(CHMP), 2006). Capsules can be compounded extemporaneously in the
dosage needed, but they need to be dissolved before administration and
are difﬁcult to administer through feeding tubes. Another disadvantage
of extemporaneously compounded capsules is the difﬁculty in obtaining
adequate content uniformity at low dosages.
Liquid formulations have the advantage of dosingﬂexibility and a re-
duced risk of choking. They can also be applied in other populations,
such as geriatric patients with swallowing difﬁculties, or in a palliative
setting. Possible disadvantages of liquid formulations are issues with
stability and palatability, parameters that need to be considered in the
design. As an alternative for liquid formulations, the development of
mini-tablets has been given a lot of attention in the past years
(Aleksovski et al., 2015). They provide dosing ﬂexibility and ease ofer the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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liquid formulations. However, for most compounding pharmacies,
tableting is not an available technique. Liquid formulations are therefore
still commonly applied by pharmacist that need to compound for paedi-
atric patients, both on individual and batch scale.
Drug substances sometimes show poor aqueous solubility. The use of
solubilizing excipients can improve this, but especially in the paediatric
population, theuse of excipients needs to be considered carefully,with re-
spect to safety and palatability. The objective of this study was to explore
different formulation strategies for a poorlywater soluble drug substance,
lorazepamwas chosen as a model drug.
Lorazepam (7-chloro-5-(2-chlorophenyl)-3-hydroxy-2,3-dihydro-
1H-1,4-benzodiazepin-2-one) is a benzodiazepine indicated for the
treatment of generalized anxiety disorder and pre-surgical (Lexicomp
Online®, 2016). Off-label, it is applied in a wide range of indications
and patient categories, because of its sedative and anticonvulsive activ-
ity and absence of active metabolites. Within paediatrics, it is adminis-
tered to children from the age of one month for acute anxiety,
sedation, chemotherapy induced- or associated nausea, status epilepti-
cus or for weaning purposes (Lexicomp Online®, 2016).
Currently, no liquid dosage form of lorazepam is available in the EU.
An extemporaneous suspension of 1mg/ml, prepared from2mg tablets,
distilled water, Ora-Plus® and Ora-Sweet®, has been proven to be
chemically stable for up to three months when stored at 4 °C (Lee et
al., 2004). However, a subsequent study using this suspension proved
that dosagemeasurement by paediatric intensive care nurses led to sig-
niﬁcant deviations from the intended dose (Lee et al., 2005). These inac-
curate dosage measurements are less likely to occur in the case of an
oral solution, but the physical and chemical characteristics of lorazepam
make this a challenge.
There are different strategies to formulate a poorly water soluble
drug substance into an oral solution. pH Adjustment can be used to ion-
ize a compound, which generally will result in increased aqueous solu-
bility. In the case of lorazepam (aqueous solubility 0.08 mg/ml) (O'Neil,
2006), with pKas of 1.3 and 11.5 (Clarke's Analysis of Drugs and Poisons
[Internet], 2016), pH adjustment is not a feasiblemethod to increase the
solubility. It is also sensitive to hydrolysis in both acidic and basic envi-
ronments (Siddegowda et al., 2012) and shows temperature-dependent
degradation (McMullan et al., 2013). Organic solvents can be used as an
alternative to water, but speciﬁc attention has to be paid to safety in
paediatric patients. A distinction can be made between water-soluble
and water-insoluble organic solvents. Water-soluble co-solvents, like
ethanol (lorazepam solubility 14 mg/ml) and propylene glycol (loraze-
pam solubility 16 mg/ml) (O'Neil, 2006), create a mixed aqueous/
organic solution. These excipients are readily available and easy to pro-
cess, but they can convey a risk of toxicity to children (Committee for
Human Medicinal Products (CHMP), 2006). A combination of water-
insoluble organic solvents, such as medium-chain and long-chain tri-
glycerides and oleic acid, can be used to disperse lipophilic drugs.Fig. 1. Lorazepam 1 mg/ml test formulations cAlternatively, a poorwater-soluble drug can be solubilized using surfac-
tants, like polysorbate 20 and 80 (Tween) or polyoxyl hydrogenated
castor oil (Cremophor), to obtain micelles in an aqueous environment.
Similarly, surfactants can be used to obtain a microemulsion, when
combined with a polar solvent, an oil, and a cosurfactant. Lastly, com-
plexation of poorly soluble drugswith cyclodextrins has been a strategy
to increase the aqueous solubility and bioavailability of compounds,
while at the same time masking the taste (Committee for Human
Medicinal Products (CHMP), 2014a), an important aspect in the design
of paediatric formulations.
The objective of this study was to explore different formulation
strategies to process a poorly soluble drug substance into a clear oral so-
lution, using lorazepam as a model drug. The formulation needed to be
suitable for paediatric patients from the age of onemonth, and have ad-
equate stability to allow for individual and batch production within the
pharmacy.
2. Material and methods
2.1. Materials
Lorazepam drug substance was bought from Fagron BV (Capelle
a/d IJssel, The Netherlands) and Duchefa Farma BV (Haarlem, The
Netherlands). Lorazepam related compound B and hydroxypropyl-
β-cyclodextrin (HP-β-CD, substitution degree 0.6) were bought
from Sigma-Aldrich Chemie BV (Zwijndrecht, The Netherlands).
Lorazepam related compounds C and D were bought from USP
Switzerland (Basel, Switzerland). Colour Reference Solutions Y
were bought from Merck Millipore (Amsterdam, The Netherlands).
Lorazepam drug substance and all other excipients were European
Pharmacopoeia grade.
2.2. Formulation development
The dosage strength was chosen based on the target population of
children from the age of one month to 18 years old, receiving a maxi-
mumdose of 0.6mg/kg/day (LexicompOnline®, 2016). To limit the vol-
ume needed and excipients administered, we aimed for a strength of
1 mg/ml. Three different formulation strategies were explored to im-
prove the solubility. Firstly, water-soluble organic solvents were used
to improve the aqueous solubility directly, secondly, non-ionic surfac-
tants were used to solubilise themodel drug, and thirdly, complexation
of lorazepamwith cyclodextrinwas studied. Parameters thatwere stud-
ied were; physical stability (by visual inspection), chemical stability,
using the analytical assay described in Section 2.5, and palatability
(see Section 2.3). Physical instability was deﬁned as the presence of vis-
ible precipitation. The visual inspection of the samples was performed
according to Ph. Eur. 2.2.1., with use of commercial reference solutions.
The physical and chemical stability were initially studied for 5 months.ontaining water-soluble organic solvents.
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For the organic solvents-based formulation, we experimented with
different ratios of propylene glycol (PG), poly ethylene glycol 400
(PEG400) and glycerol 85%. Efforts were directed towards a glycerol/
PEG400 basedmixture containingminimal amounts of propylene glycol
(Fig. 1).
2.2.2. Non-ionic surfactants
The second strategy that was explored was the use of non-ionic
surfactants to create a micellar solution. Polysorbate 80 and sorbitan
monooleate were mixed in a ratio to obtain a hydrophilic/lipophilic
balance (HLB) of 11.5. The total surfactant content in the test formu-
lations ranged from 1 to 5%. PEG400 was used to dissolve lorazepam,
after which the micellar solution was slowly added to the PEG400.
The volume per test formulation was 50 ml, the composition of the
excipients is displayed in Fig. 2.
2.2.3. Cyclodextrin
For the cyclodextrin formulation, HP-β-CD was chosen as the
complexing agent, because of its high water solubility, lower cost com-
pared to other cyclodextrins, low toxicity (Committee for Human
Medicinal Products (CHMP), 2014a), and based on previouswork investi-
gating different cyclodextrins for inclusion complexation of lorazepam
(Holvoet et al., 2005). A phase solubility diagram was made to measure
the solubility of lorazepam as a function of the HP-β-CD concentration.
This revealed that a minimum of 54 mg/ml HP-β-CDwas required to ob-
tain a 1mg/ml lorazepam solution after 4 h of ultrasoniﬁcation. However,
a HP-β-CD solution of 60mg/ml (formulation C1) proved not sufﬁcient to
maintain a stable product after one week, therefor the HP-β-CD concen-
tration was increased to 100 mg/ml (formulation C2). Glycerol 85% was
added as a preservative in an amount of 35% m/v.
2.3. Palatability
The palatability of the test formulations was assessed by three
adults, experienced in taste assessment. Characteristics that were eval-
uated were smell, taste, aftertaste and mouthfeel, and they were inde-
pendently and qualitatively described by the taste panel. Taste
correction possibilities were assessed with formulation C2, O6 and O7,
using lemon, banana, raspberry and orange essence. Raspberry and ba-
nana were chosen as they are regularly applied in paediatric formula-
tions. Lemon and orange ﬂavours are good taste maskers for bitter
drug substances.
2.4. Long-term stability studies
After the preliminary formulation studies, a decision was made to
continue the development with formulation O7 (Table 3). To thisFig. 2. Lorazepam 1 mg/ml test formulatioend, two batches of 3000 ml each were compounded, to investigate
the inﬂuence of temperature and packaging material on long term
stability. The test formulations were prepared with active pharma-
ceutical ingredient (API) from two different suppliers (Fabbrica
Italiana Sintetici S.p.A and Cambrex Profarmaco Milano S.r.l.). Sam-
ples were stored in climate cabinets at 4 °C (VTL650K, range 2–
8 °C) and 25 °C 60% relative humidity (Elbanon type LC 500, range
23–27 °C, 55–65% RH) in amber-coloured polyethylene terephthal-
ate (PET) and glass containers. In each cabinet the temperature was
registered hourly. Because of the known temperature dependent
degradation of lorazepam, stability studies at 40 °C were omitted.
Samples were tested against the release or end-of-shelf life speciﬁca-
tions, based on the United States Pharmacopeia (USP) monograph
for lorazepam oral concentrate and the general Ph. Eur. monograph
for microbiological quality of non-sterile pharmaceutical prepara-
tions, shown in Table 1. Samples stored at 25 °C were analysed at 0,
1, 2, and 3 months. Samples stored at 4 °C were also analysed at 6,
9 and 12 months.
2.5. Analytical assay
For the quantitative analysis of lorazepam and lorazepam related
compounds (USP) B, C and D [2-amino-2,5″-dichlorobenzophenone, 6-
chloro-4-(o-chlorophenyl)-2-quinazolinecarboxaldehyde and 6-chloro-
4-(o-chlorophenyl)-2-quinazolinecarboxylic acid, respectively] a high
performance liquid chromatography combined with UV (HPLC-UV) de-
tection method was used. The components were separated using a
Shimadzu LC20 system, on a C18 analytical column (Inertsil ODS-3.5 μm
150 × 4.6 mm) with a mixture of acetonitrile, methanol and ammonium
acetate solution (100mM, pH 6.0±0.04 adjustedwith 1Macetic acid) in
the ratio 1:1:1 (v/v/v) as mobile phase, at a ﬂow rate of 1.0 ml/min. Col-
umn temperature was kept at 30 ± 0.1 °C and UV detection for quantiﬁ-
cation was performed at 230 nm using a Shimadzu M20A diode array
detector, while the wavelength range of 200–400 nm was continuously
monitored for unidentiﬁed peaks. The injection volume was 20 μl. The
methodwas validated for the quantiﬁcation of lorazepam in the cyclodex-
trin and PG/PEG 400/glycerol sample matrices and in the presence of re-
lated compounds B, C and D, for the parameters shown in Table 2. The
response factors of related compounds B, C and D were determined to
allow for accurate quantiﬁcation of these compounds on lorazepam cali-
bration curves.
2.6. Calibration and sample analysis
Samples were diluted 40 times to 25 μg/ml with mobile phase and
quantiﬁed on a calibration curve (20–30 μg/ml) of freshly prepared stan-
dard solutions of lorazepam RS in mobile phase using the validated HPLC
method. All duplicate sample analyses were preceded by a systemns containing non-ionic surfactants.
Table 2
Validation parameters of the developed HPLC-UV analytical assay.
LLOQ lower limit of quantiﬁcation, LOD limit of detection.
Parameter Test n Speciﬁcation Result
Accuracy (12.5–37.5 μg/ml) Recovery (%) 12 98.0–102.0 100.0
Coefﬁcient of variation
(%)
12 b1.0 0.5
Linearity (0–1.25 μg/ml) F-value (12;1
p = 0.05)
14 b4.747 1.508
Correlation coefﬁcient 14 N0.9950 0.9978
Linearity (12.5–37.5 μg/ml) F-value (10;1 12 b4.965 2.050
Fig. 3. Average lorazepam content (left graph) with SD (n = 4) and related compound C content (right graph) with SD (n = 4) of formulation O7 at 4 and 25 °C.
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ture of lorazepam RS 25 μg/ml in mobile phase and lorazepam related
compound D, 25 μg/ml RS in mobile phase. Speciﬁcations for the relative
standard deviation in the lorazepam peak areas and the resolution be-
tween the lorazepam and lorazepam related compound D peaks were
≤0.5% and 3.8–4.6, respectively. If unavailable, lorazepam related com-
pound D can be created in situ by diluting a lorazepam RS 1000 μg/ml so-
lution in methanol 40 times with 1 M sodium hydroxide and exposing it
to a temperature of 70 °C for two hours, then neutralized by mixing with
an equal volume of 1 M hydrochloric acid.
2.7. In-use stability
An in-use testwas performed on theﬁnal formulation (O7) based on a
four-times daily dosing schedule. The containers were stored at 4 °C
(range 2–8 °C) and based on the application in our PICU, four-times
daily removed from the climate chamber to be exposed to air, light and
ambient temperature for 15 min at every dosing simulation. Samples of
0.25 ml were withdrawn. After 28 days the samples were analysed in ac-
cordance with the speciﬁcations in Table 1. Microbiological quality was
tested in accordance with the bioburden ﬁltration method of Ph. Eur.
2.6.1.
2.8. Manufacturing procedure
Themanufacturing procedurewas developedwith the intention to be
suitable for individual and batch compounding. The lorazepam drug sub-
stancewas levigated in amortarwith the solventmixture. The remaining
solvent was added by geometric dilution. Orange essence was added and
the solutionwasmagnetically stirred for onehour to achieve complete so-
lution of the lorazepam.Table 1
Release and end-of-shelf life speciﬁcations.
Test item Method Reference Acceptance criteria
Identiﬁcation According to
assay
Ph. Eur.
Lorazepam
Monograph
Spectra should be identical
to reference
Appearance Visual
observation
Ph. Eur. 2.2.1 Clarity ≤ Susp. I
Ph. Eur. 2.2.2 Coloration ≤ Y5
Assay HPLC-UV Modiﬁed Ph. Eur.
method
Lorazepam 90–110%
Related compound C ≤ 4%
Sum of other related
compounds ≤2%
Microbiological
quality
Bioburden
ﬁltration
Ph. Eur. 2.6.1. E. coli Absent
TAMC (CFU/ml) b 100
TYMC (CFU/ml) b 10
CFU Colony-forming unit TAMC Total aerobic microbial count TYMC Total combined
yeasts/moulds count.3. Results
3.1. Formulation development
The organic solvents-based formulations O1–O7 all resulted in physi-
cally stable products for at least 5 months. In formulation O1–O4, the lor-
azepam content declined to around 80–90% after 5 months at 4 °C.
FormulationsO5–O7were also chemically stable,with lorazepamcontent
remaining around 100% after ﬁve months at 4 °C. For this reason, we
chose formulation O7, with the lowest propylene glycol content, to take
into further development (Table 3).
The surfactant-based formulations gave variable results. Formula-
tions S1–S3 precipitated within a few days (S1) to two months (S3).
Formulations S4–S6 remained physically stable during the study period.
The content of S4 declined towards the end-of-shelf life limit of 90%
within 3 months at 4 °C. S5 and S6 remained chemically stable, but de-
velopment of these formulationswas discontinued due to the bad soapy
taste of the liquid.
The cyclodextrin formulation C2 containing 100 mg/ml HP-β-CD
remained physically stable during the 5 month study period. Thep = 0.05)
Correlation coefﬁcient 12 N0.9950 0.9997
Limits LLOQ (μg/ml) 26 – 0.055
LOD (μg/ml) 26 – 0.018
Intra-assay precision
(0.25 μg/ml)
Coefﬁcient of variation
(%)
6 b1.0 0.2
Intra-assay precision
(25 μg/ml)
Coefﬁcient of variation
(%)
6 b1.0 0.1
Inter-assay precision
(25 μg/ml)
Coefﬁcient of variation
(%)
6 b2.0 1.4
Response factors Related compound B 4 – 0.707
Related compound C 4 – 1.085
Related compound D 4 – 0.999
Speciﬁcity Lorazepam (%) 2 N99.5 99.7
Related compound B
(%)
2 N99.5 99.9
Related compound C
(%)
2 N99.5 99.8
Related compound D
(%)
2 N99.5 99.6
Table 3
Composition of the lorazepam formulation studied for long-term and in-use stability.
Lorazepam 100 mg
Poly ethylene glycol 400 10 g
Propylene glycol 3 g
Orange essence 100 mg
Glycerol 85% ad 108,1 g (=100 ml)
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formation of related substance C up to 2,9%.
3.2. Palatability
The taste assessment results within the panel were consistent.
Both cyclodextrin formulations had a neutral scent, slightly sweet
taste, and a faint bitter taste caused by the lorazepam. There was
no obvious aftertaste, but a prickly sensation on the tongue was
sometimes observed. The lemon essence was the preferred taste cor-
rector for formulation C2. Formulations S4 and S4 both had an
overpowering soapy smell and taste, which was the reason for
discontinuing the development of the surfactant-based formula-
tions. All organic solvent-based formulations had a neutral scent, a
sweet taste and a bitter aftertaste. Formulations with 20% PEG400
had a stronger bitter taste than formulations with 10% PEG400.
Orange essence was the preferred taste corrector for formulation
O6 and O7.
3.3. Long-term stability
The long-term chemical stability studies of formulation O7
showed that lorazepam content declined over time as displayed in
Fig. 3. A gradual increase in related compounds, mainly related com-
pound C, was seen in all samples, but was notably higher at 25 °C.
Therefore, stability studies at 25 °C were stopped after 3 months.
At 12 months, related compound B was ﬁrst measured in the 4 °C
samples and also an unknown impurity was found. Related
compound C remained below 2.0%. The packaging material did not
inﬂuence the chemical degradation of lorazepam. No changes in
colour and clarity were observed in any of the samples.
3.4. In-use stability
The samples of formulation O7 remained stable during the in-use
study, no visual changes were observed. The content of lorazepam
did not decrease during the in-use study. Related substance C
reached a maximum of 0.5% and the remaining related substances
were all below the quantiﬁcation limit. The total aerobic microbial
count and total yeast and mould counts were b1 colony forming
unit per sample (the total remaining liquid per vial) at day 28 of
the in-use study in all samples.
4. Discussion
In this study, we explored different formulation strategies to
compound a poorly water-soluble drug into a clear oral liquid
formulation, using lorazepam as a model drug. With the intended
application in paediatric patients, speciﬁc attention was paid to
child-friendly excipients and adequate palatability. We developed
an oral solution of lorazepam at a concentration of 1 mg/ml with
adequate physical and chemical stability, and a shelf-life of at least
12 months. This clear solution can be expected to provide good
dosing accuracy.
In our ﬁnal, organic solvent based formulation, a small volume
(3% m/v) propylene glycol was still needed to ensure adequate
stability. Recently the European Medicines Agency has published anew assessment report concerning the safety of propylene glycol in
paediatric formulations (Committee for Human Medicinal Products
(CHMP), 2014b). In this report, new safety limits were set, expressed
in terms of maximum daily doses that are considered to be safe
whatever the duration and the route of administration. For neonates
up to 28 days, this limit is set at 1 mg/kg, for children 1 month to
4 years old it is set at 50 mg/kg, and for children aged ﬁve years
and up it is set at 500 mg/kg. Even in the rare occasion that the
maximum dose of 0.6 mg/kg/day is required, the intake limits for pa-
tients above 28 days old will not be reached with our formulation. If
administration to neonates is required, the propylene glycol limit of
1 mg/kg/day may be exceeded, and therefore its use is not
recommended for neonates.
In the last decades, an increasing amount of research has been per-
formed into cyclodextrins as a pharmaceutical excipient. The best
known example of cyclodextrin in a commercial formulation, is
itraconazole (Trisporal®) 10 mg/ml oral solution, containing 40% HP-
β-CD and 2,5% propylene glycol, which is used off-label in children.
HP-β-CD seems to be a promising option for a lorazepamsolution. How-
ever, our results showed a restricted stability of maximum of 5 months,
most likely due to hydrolysis of lorazepam. The compounding method,
needing 4 h of ultrasoniﬁcation, proved impractical for individual prep-
arations. The high amount of HP-β-CD required in this composition also
makes it expensive. A possible solution that is currently being studied is
the spray-drying of lorazepam-cyclodextrin 1:1 complexes, to provide a
dry, and thus stable, semi-ﬁnished product, which can be compounded
by pharmacist for individual patients.
Besides the technical challenges, there are also uncertainties around
the safety of cyclodextrins in children below the age of 2 years. The oral
bioavailability of HP-β-CD is very low, and high doses could cause re-
versible diarrhoea. For children below the age of 2 years, the currently
suggested permitted daily exposure of HP-β-CD is set at 16 mg/kg/day
for oral ingestion (Committee for Human Medicinal Products (CHMP),
2014a). This is set at one tenth of the adult value, as there are insufﬁ-
cient data in this age group. It corresponds with a maximum allowable
lorazepam intake of 0.16mg/kg/day, whichmay be surpassed in clinical
practice. In summary, a cyclodextrin formulation is a feasible option, but
would require considerable additional research.
Our efforts to create a micellar solution of lorazepam resulted in a
physically and chemically stable product, and the high amounts of sur-
factants required to obtain a stable solution would not exceed the Ac-
ceptable Daily Intake (ADI) limits for food additives set by the WHO
(Joint FAO/WHO Expert Committee on Food Additives Meeting, World
Health Organization, International Program on Chemical Safety,
editors, 1982; Joint FAO/WHO Expert Committee on Food Additives,
editor, 1974). However, the taste of the formulation made it unaccept-
able for use in children. The development of this formulationwas there-
fore discontinued.
With regard to the palatability assessment by healthy volunteers, it
is known that children experience different taste sensations than adults
(Mennella and Beauchamp, 2008). In this stage of developmentwe con-
sidered a ﬁrst screening by an adult tasting panel acceptable. A palat-
ability assessment is included in the clinical trial that is currently
performed with our formulation in paediatric ICU patients.
In conclusion, we have studied different options for an oral solution
of a poorly water soluble drug, using lorazepam a model drug. The or-
ganic solvent based formulation showed adequate stability, taste and
dosing ﬂexibility, rendering it suitable for the paediatric population
above the age of one month. Our ﬁnal, organic solvent-based formula-
tion is currently used in a paediatric clinical trial to study the oral phar-
macokinetics of lorazepam in PICU patients from the age of 1 month to
12 years old. This formulation is preferable to manipulation of
commercial dosage forms and non-standardized extemporaneously
compounded formulations, and may serve as an example for the
development of comparable drug substances into oral liquid
formulations.
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